| scholarly article | Q13442814 |
| P2093 | author name string | Petr Ostadal | |
| David Alan | |||
| Jiri Vejvoda | |||
| P2860 | cites work | Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque | Q24339425 |
| Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696] | Q24806340 | ||
| Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels | Q28176954 | ||
| Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 | ||
| Novel clinical markers of vascular wall inflammation | Q28190821 | ||
| Atherosclerosis: the new view | Q28192780 | ||
| Early statin initiation and outcomes in patients with acute coronary syndromes | Q28193226 | ||
| HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins | Q28344912 | ||
| Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes | Q28359694 | ||
| Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells | Q28379577 | ||
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. | Q31387811 | ||
| Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization | Q31956534 | ||
| An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro | Q32033463 | ||
| Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia | Q32129328 | ||
| Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries | Q72085509 | ||
| Targeting Rho in cardiovascular disease | Q73015340 | ||
| Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl | Q73074808 | ||
| Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL | Q73112077 | ||
| Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women | Q73157102 | ||
| Superoxide anion scavenging properties of fluvastatin and its metabolites | Q73162122 | ||
| Hypercoagulable state in hypercholesterolemic subjects assessed by platelet-dependent thrombin generation: in vitro effect of cerivastatin | Q73182838 | ||
| Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease | Q73190007 | ||
| Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study) | Q73289471 | ||
| HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells | Q73435193 | ||
| Platelet-dependent thrombin generation in patients with hyperlipidemia | Q73476741 | ||
| Early statin treatment following acute myocardial infarction and 1-year survival | Q73595077 | ||
| Inhibition of monocyte chemotactic protein-1 synthesis by statins | Q74045131 | ||
| Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells | Q74119638 | ||
| Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro | Q74484834 | ||
| HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis | Q77700153 | ||
| Statins and monocytes | Q77904872 | ||
| Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial | Q77933067 | ||
| Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts | Q77990821 | ||
| An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor | Q78089782 | ||
| Nitric oxide and the proliferation of vascular smooth muscle cells | Q33847601 | ||
| Changing concepts of atherogenesis | Q33890391 | ||
| Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial | Q33940282 | ||
| Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels | Q33942737 | ||
| Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. | Q34429041 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial | Q34550538 | ||
| Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress | Q34658022 | ||
| Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes | Q35200997 | ||
| Towards understanding acute destabilization of vulnerable atherosclerotic plaques | Q35542584 | ||
| Early vascular benefits of statin therapy | Q35574104 | ||
| The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach | Q35744631 | ||
| Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines | Q35749970 | ||
| Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects | Q35804090 | ||
| Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability | Q37361893 | ||
| Hemostasis and atherosclerosis. | Q40525600 | ||
| Early statin therapy restores endothelial function in children with familial hypercholesterolemia | Q40613252 | ||
| Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial | Q40616674 | ||
| Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor--I in human endothelial cell cultures | Q40776539 | ||
| 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins | Q41005307 | ||
| Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels | Q41110144 | ||
| Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line | Q41152300 | ||
| Statins do more than just lower cholesterol | Q41169571 | ||
| The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction | Q42164942 | ||
| Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells | Q42493329 | ||
| Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients | Q43515062 | ||
| Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study | Q43571946 | ||
| HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury | Q43626599 | ||
| Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet | Q43654962 | ||
| Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days | Q43684740 | ||
| Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. | Q43686071 | ||
| Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction | Q43721244 | ||
| Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin | Q43895513 | ||
| Withdrawal of statins increases event rates in patients with acute coronary syndromes | Q43933090 | ||
| Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women | Q43943280 | ||
| Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease | Q43955489 | ||
| Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering | Q43957656 | ||
| Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways | Q43961145 | ||
| Short-term effects of atorvastatin on C-reactive protein | Q43992481 | ||
| Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice | Q44007043 | ||
| Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes | Q44011973 | ||
| Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes | Q44016826 | ||
| Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects | Q44021803 | ||
| Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes | Q44026877 | ||
| Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial | Q44036282 | ||
| Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. | Q44063984 | ||
| Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes | Q44064914 | ||
| The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells | Q44134020 | ||
| Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects | Q44165719 | ||
| Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering | Q44173347 | ||
| Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus | Q44249465 | ||
| Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis. | Q44269540 | ||
| hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation | Q44292384 | ||
| Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway | Q44307951 | ||
| Effect of atorvastatin and pravastatin on serum C-reactive protein | Q44321723 | ||
| High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study | Q44585429 | ||
| Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial | Q44950890 | ||
| Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction | Q45098728 | ||
| Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway | Q45099728 | ||
| Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction | Q45712799 | ||
| Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction | Q47252034 | ||
| Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia | Q47887085 | ||
| Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. | Q50225902 | ||
| Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. | Q50277148 | ||
| Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. | Q51558882 | ||
| Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. | Q52218975 | ||
| Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. | Q52541795 | ||
| Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
| Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. | Q53965155 | ||
| Statin therapy and the acute inflammatory response after coronary artery bypass grafting | Q57243098 | ||
| Vastatins Inhibit Tissue Factor in Cultured Human Macrophages | Q57398943 | ||
| Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells | Q58106726 | ||
| Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia | Q58421218 | ||
| Inhibition of tissue-factor-mediated thrombin generation by simvastatin | Q58421229 | ||
| Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol | Q59536862 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Fibrinogen as a risk factor for stroke and myocardial infarction | Q71438059 | ||
| Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II Hyperlipoproteinemia | Q71843129 | ||
| Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture | Q72034135 | ||
| P433 | issue | 1 | |
| P921 | main subject | aspirin | Q18216 |
| acute coronary syndrome | Q266018 | ||
| P304 | page(s) | 9-16 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Experimental & Clinical Cardiology | Q5421099 |
| P1476 | title | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? | |
| P478 | volume | 10 |
Search more.